Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034853 · ClinicalTrials.gov registry record · Phase 3
Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
NCT00034853 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 180 participants.
The verdict
NCT00034853, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
Study Summary
To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)
Interventions
- DRUG meloxicam oral suspension
- DRUG naproxen oral suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2000-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00034853
The ClinicalTrials.gov registry entry for NCT00034853 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which meloxicam oral suspension is the first listed.
NCT00034853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00034853 about?
NCT00034853 is a clinical study titled "Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)". To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)
What is the current status of trial NCT00034853?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2000-12.
What interventions are being tested in trial NCT00034853?
The interventions under investigation include: meloxicam oral suspension (DRUG), naproxen oral suspension (DRUG).
Who is sponsoring clinical trial NCT00034853?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.